Nyrada
Menu
NYR:
Market Cap*:
Price Delay ~20min
Home
About Us
Company Overview
Board of Directors
Management
Scientific Advisory Board
Corporate Governance
Our Science
Lead Drug Development
Cholesterol-Lowering Program
Brain Injury Program
Technical Glossary
Drug Development Pathway
Investors
Investor Welcome
ASX Announcements
Brain Injury Program
Cholesterol-Lowering Program
Financial Reports
Corporate Announcements
Investor Presentations
Share Price Information
Key Dates
Investors Glossary
Annual Reports
Analyst Reports
Annual General Meeting
Past Shareholder Meetings
News & Insights
Presentations & Interviews
Media
Newsletters
Publications
Contact Us
Contact Us
Working at Nyrada
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Welcome
ASX Announcements
Brain Injury Program
Cholesterol-Lowering Program
Financial Reports
Corporate Announcements
Investor Presentations
Share Price Information
Key Dates
Investors Glossary
Annual Reports
Analyst Reports
Annual General Meeting
Past Shareholder Meetings
ASX Announcements
Filter by Year:
2023
2022
2021
2020
11-May-2021
Notice of Extraordinary General Meeting/Proxy Form
6-May-2021
Nyrada Receives A$1.0M R&D Tax Incentive Rebate
5-May-2021
NYR Announces New Potent Cholesterol-Lowering Candidates
26-Apr-2021
Change of Registered Office and Principal Place of Business
20-Apr-2021
Nyrada Quarterly Activities Report & Appendix 4C
30-Mar-2021
Change in substantial holding
30-Mar-2021
Ceasing to be a substantial holder
30-Mar-2021
Change in substantial holding
30-Mar-2021
Cleansing Statement
30-Mar-2021
Appendix 2A
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
Next